Isemid (11.5 - 23 kg)
Active substance
ATC code
Species
Dogs.
Indications
For treatment of clinical signs related to congestive heart failure in dogs, including pulmonary oedema.
Dose to be administered and administration route
Oral use.
The recommended initial/maintenance dose is 0.13 to 0.25 mg torasemide/kg bodyweight/day, once daily.
In case of moderate or severe pulmonary oedema, this dose can be increased if necessary up to a maximum dose of 0.4 mg/kg bodyweight/day once daily.
Doses of 0.26 mg/kg and higher should only be administered for a maximum period of 5 days. After this period, the dose should be reduced to the maintenance dose and the dog should be evaluated by the veterinarian in a few days.
The following table shows the dose adjustment scheme within the recommended dose range of 0.13 to 0.4 mg/kg/day:
Dog Bodyweight (kg) | Number and strength of Isemid chewable tablets to be administered | |
Initial/Maintenance dose (0.13 to 0.25 mg/kg/day) | Temporary high dose (0.26 to 0.40 mg/kg/day) | |
1 mg | ||
2.5 to 4 | ½ | 1 |
> 4 to 6 | 1 | 1 + ½ |
> 6 to 8 | From 1 to 1 + ½ | From 2 to 2 + ½ |
> 8 to 11.5 | From 1 + ½ to 2 | From 2 + ½ to 3 |
2 mg | ||
> 11.5 to 15 | From 1 to 1 + ½ | 2 |
> 15 to 23 | From 1 + ½ to 2 | From 2 + ½ to 3 |
4 mg | ||
> 23 to 30 | From 1 to 1 + ½ | 2 |
> 30 to 40 | From 1 + ½ to 2 | From 2 + ½ to 3 |
> 40 to 60 | From 2 to 2 + ½ | From 3 to 4 |
The dose should be adjusted to maintain patient comfort with attention to renal function and electrolytes status. Once signs of congestive heart failure have been controlled and the patient is stable, it should be continued at the lowest effective dose, if long term diuretic therapy with this product is required.
If the chewable tablet is not spontaneously taken by the dog, it can also be given with food or directly into the mouth.
Adverse reactions
Dogs:
|
Very common (>1 animal / 10 animals treated): |
Renal insufficiency Elevated renal parameters Electrolyte disorder1 Haemoconcentration. |
|
Common (1 to 10 animals / 100 animals treated): |
Digestive tract disorders2 (e.g. vomiting, diarrhoea) Polyuria, Urinary incontinence Anorexia, Dehydration, Weight loss, Lethargy, Polydipsia. |
|
Undetermined frequency (cannot be estimated from the available data) |
Dry mucous membrane (oral)3, Alkaline urine3, Decreased urine concentration3, Increases in glucose and aldosterone serum concentrations3 (reversible). |
1 Alterations in chloride, sodium, potassium, phosphorus, magnesium and calcium levels
2 These signs are episodic.
3 Effects consistent with the pharmacological activity of torasemide observed in healthy dogs at the recommended dose.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | 15052/5009 |
| EAN | 3411113061074 |
